Roche nabs European OK for Rituxan heir Gazyvaro; GSK dividend probably safe, analysts say;

@FiercePharma: Why are Anoro & Breo slow starters? GSK's new quota-free model, critics say. More | Follow @FiercePharma

@TracyStaton: On Pfizer, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton

@EricPFierce: Impax shares take a thrashing after FDA issues Taiwan plant new Form 483 with 10 observations. Article | Follow @EricPFierce

@CarlyHFierce: Merck spokeswoman: Sales layoffs to hit PA-based field reps. Story | Follow @CarlyHFierce

> Roche ($RHHBY) won European approval for its chronic lymphocytic leukemia treatment, Gazyvaro, in another step toward turning the drug into a blockbuster successor to Rituxan. Release | Report (sub. req.)

> Despite GlaxoSmithKline's ($GSK) disappointing second-quarter results, analysts figure that its dividend is likely safe, at least for now. Report

> Ranbaxy Laboratories suffered a quarterly loss after yet another import ban because of quality problems at an Indian plant. Report

> Recent hedge fund filings show that U.S. drugmaker Bristol-Myers Squibb ($BMY) has fans in that slice of the investment world. Report

> Italy's Recordati boosted profits by 18% in the first half of 2014, thanks to a 6% increase in sales, to €507.6 million. Report

> Brazilian drugmaker Hypermarcas doesn't see any ripe opportunities for dealmaking, CEO Claudio Bergamo says. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Google wearables to add to planned bioinformatics database. Article | Follow @FierceMedDev

@StacyALawrence: Medtronic teaming up with China's LifeTech to develop cardiovascular products. More | Follow @StacyALawrence

@VarunSaxena2: FDA final guidance modifies 510(k) rules, discourages use of multiple predicate devices. Story | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: FDA and physicians question the validity of popular mobile medical health apps. More from Wired | Follow @EmilyWFierce

> Wearable optical device detects diabetic complication. More

> Proteus Digital adds $52M to Series G, bringing total to $172M. News

> French devicemaker faces FDA scrutiny for prostate cancer device. Article

Biotech News

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals. Article | Follow @JohnCFierce

@DamianFierce: $GSK has launched Tanzeum (albiglutide) in the U.S., further crowding the GLP-1 market for T2 diabetes. Press release | Follow @DamianFierce

@EmilyMFierce: Really cool, albeit potentially terrifying: Teeth Sprout from Glia-Derived Stem Cells. GEN piece | Follow @EmilyMFierce

> Pfizer, Lilly and J&J chip in on $51M seed fund for New York biotechs. News

> Targacept's litany of trial failures continues with yet another flop. Article

> Sanofi dumps KaloBios' antibiotic in another stinging setback. More

Biotech Research News

> NIH to spur innovation in new therapeutic areas. News

> Janssen rethinks drug discovery in a changing R&D environment. More

> Anti-inflammatory drug stops Parkinson's neuron loss in rats. Article

> CDC takes steps to improve lab safety after anthrax, flu scares. Story

> Vaccine protects animals against dust mite allergies. Item

Pharma Manufacturing News

> Impax now faces FDA issues at Taiwan plant that could affect Rytary. Report

> PCI buys contract manufacturer Penn Pharma in $215M deal. Story

> Merck KGaA to cut carbon dioxide emissions at Darmstadt site. More

> Hikma buys closed Boehringer plant and strips out equipment. News

> J&J done with Boehringer plant after building a supply of Doxil. Article

And Finally... The quantified-fitness company Jawbone launched an app to track caffeine consumption, UP Coffee. Report